Projay

What are probiotics and prebiotics?

Answer From Katherine Zeratsky, R.D.,L.D.

Probiotics are foods or supplements that contain live microorganisms intended to maintain or improve the “good” bacteria (normal microflora) in the body. Prebiotics are foods (typically high-fiber foods) that act as food for human microflora. Prebiotics are used with the intention of improving the balance of these microorganisms.

Probiotics are in foods such as yogurt and sauerkraut. Prebiotics are in foods such as whole grains, bananas, greens, onions, garlic, soybeans and artichokes. In addition, probiotics and prebiotics are added to some foods and available as dietary supplements.

Research is ongoing into the relationship of the gut microflora to disease. The health benefits of currently available probiotics and prebiotics have not been conclusively proved.

However, side effects are rare, and most healthy adults can safely add foods that contain prebiotics and probiotics to their diets. Future research may lead to advanced probiotics with greater potential to improve health.

If you’re considering taking supplements, check with your doctor to be sure they’re right for you.

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. In contrast, prebiotics are nondigestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon.

Probiotics might: Help your body maintain a healthy community of microorganisms or help your body’s community of microorganisms return to a healthy condition after being disturbed. Produce substances that have desirable effects. Influence your body’s immune response.

Are probiotics safe for use during pregnancy and lactation?

Jackie Elias, RPh, Pina Bozzo, and Adrienne Einarson, RN

Additional article information

Abstract

Question There has been a great deal of discussion in both the medical and lay literature about the use of probiotics to improve general health. Subsequently, pregnant women have been asking me if probiotics used for treating conditions such as bacterial vaginosis and diarrhea are safe to use during pregnancy and lactation.

Answer Current data suggest that probiotic supplementation is rarely systemically absorbed when used by healthy individuals. One meta-analysis and several randomized controlled trials conducted with women during the third trimester of pregnancy did not report an increase in adverse fetal outcomes. There have been no published studies addressing Saccharomyces species use in pregnancy. Probiotics are unlikely to be transferred into breast milk.

Probiotics are live microorganisms (in most cases bacteria) that are similar to beneficial microorganisms found naturally in the human gut. They are available to consumers mainly in the form of dietary supplements and foods, and “when administered in adequate amounts confer a health benefit on the host.”! The most widely used probiotics in Canada are live bacteria such as Lactobacillus and Bifidobacterium species and nonpathogenic yeast such as Saccharomyces. They are available alone or in combination as tablets, drops, liquids, and oral or vaginal capsules; they are also contained in various fermented foods, most commonly yogurt. Probiotics have been used for the treatment of acute diarrhea, antibiotic-associated diarrhea, Clostridium difficile, and yeast and bacterial vaginosis. In healthy humans, lactobacilli are normally present in the oral cavity, ileum, colon, and vagina.

Product safety

When ingested orally or used vaginally, probiotics are generally considered safe and are well tolerated. One theoretical concern associated with probiotics is the potential for these organisms to cause systemic infections. Although rare, probiotic-related bacteremia and fungemia have been reported.? It is estimated that the risk of developing bacteremia from ingested

Lactobacillus probiotics is less than 1 per 1 million users,’ and the risk of developing fungemia from Saccharomyces boulardii is estimated at 1 per 5.6 million users, and is estimated to be lower in healthy individuals.* There have been no reports of bifidobacterium sepsis associated with the use of probiotics in healthy individuals.

Risk factors for systemic infections include immunosuppression, critical illness, central venous catheters, and impairment of the intestinal epithelial barrier:3 Probiotics administered orally to combat urogenital infections are not systemically absorbed but rather get to the site of action by passage through the gastrointestinal system and ascending into the vagina.

Use in pregnancy

Because the risk of probiotic-induced

bacteremia and fungemia is low, probiotics are unlikely to reach the systemic circulation of the fetus, and therefore are unlikely to cause harm. A meta-analysis and systematic review of 8 randomized control trials of probiotic use in more than 1500 pregnant women was published.” Most of the women began probiotic treatment between 32 and 36 weeks’ gestation and continued until delivery. The studies included in the meta-analysis compared Lactobacillus spp alone or in combination with Bifidobacterium spp with placebo. There was no increase in the incidence of miscarriages or malformations, which was expected because probiotic use mostly occurred in the third trimester and was therefore unlikely to affect organogenesis. There was no significant difference in birth weight, gestational age, or the incidence of cesarean section.

Several randomized control trials conducted in pregnant women in the third trimester of pregnancy were published following the meta-analysis (Table 1).8-15 These studies examined Lactobacillus spp and

Bifidobacterium spp as monotherapy or in combination. Although not designed to directly evaluate pregnancy outcomes, these studies did not suggest an increase in adverse outcomes related to probiotics. Two observational studies examining the use of lactobacilli in the first trimester of pregnancy reported no increased risk of malformations.

Randomized placebo-control trials of probiotics exposure during pregnancy

There are 2 published randomized control trials 1,15 of women exposed to probiotics commencing in the first trimester until the end of exclusive breastfeeding (Table 1). Both studies examined the combination of Lactobacillus rhamnosus strain GG and Bifidobacterium lactis compared with placebo. Neither study was specifically designed to examine pregnancy outcomes; therefore, malformations were not reported.

Luoto et allS found that infants born to women in the probiotics group had statistically significant lower risk of increased birth weight (P = .035) and birth length (P = .028); however, the clinical significance of this slight difference is unknown. This finding was not confirmed in the study by Huurre et al.I Both studies demonstrated no significant difference in gestational age or the incidence of cesarean section. There have been no published studies addressing Saccharomyces spp as an intervention for pregnant women.

Use in breastfeeding

Because probiotics are rarely systemically absorbed, they are not expected to transfer into breast milk. One randomized control trial examined Lactobacillus reuteri levels in 174 colostrum samples after maternal and infant oral supplementation of this probiotic. 18 Although higher in the active than in the placebo group, the prevalence of L reuteri in colostrum was low and not clinically important. Abrahamsson et al 8 clinically important. Abrahamsson et al 8 suggested that the most likely origin of L reuteri in colostrum was external contamination from the gastrointestinal tract. There are no published data regarding adverse effects in breastfed infants. In several of the studies previously mentioned, 10,12-14 infants received probiotic therapy after delivery without an increase in adverse effects.

Conclusion

Probiotics do not appear to pose any safety concerns for pregnant and lactating women. Systemic absorption is rare when probiotics are used by healthy individuals, and the current literature does not indicate an increase in adverse pregnancy outcomes.

Notes

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Ms Elias is a doctoral candidate in the Faculty of Pharmacy at the University of Toronto. At the time this paper was written, Ms Bozzo was a member and Ms Einarson was Assistant Director of the Motherisk Program. Ms Bozzo is now Assissant Director and Ms Einarson continues to be a member of the Motherisk Program.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.